Studies addressing rheumatoid arthritis (RA) flares, a potential new drug for psoriatic arthritis, and a novel agent in the treatment of active RA are among the highlights
Search results for: psoriatic arthritis
Treatment Patterns and Trends for Spondylarthropathies
Methotrexate is a commonly used disease-modifying antirheumatic drug (DMARD) for treating patients with psoriatic arthritis (PsA). However, is it truly as effective as many think it is? That’s the question raised during the session “Spondylarthropathies: Recent Insights,” which took place at the 2011 ACR/ARHP Annual Scientific Meeting in November.
Key Research in Vasculitis Encapsulated
Summaries of selected research abstracts on the assessment & management of systemic vasculitis from ACR Convergence 2024.
JAK Inhibitors 101
Experts provided an in-depth review of Janus kinase (JAK) inhibitors, discussing the latest research on their use in the treatment of specific rheumatic conditions, the risks associated with them and more.
Finding the Panacea
In a session at EULAR 2025, Dr. Laura Coates discussed the management of PsA, providing insights into the current research and when clinicians may want to consider prescribing specific medications.
Rheumatology Influencers: Dr. Christopher Morris’ Approach to Leadership
Dr. Christopher Morris discusses his approach to training the next generation of rheumatologists to account for disparities in access to rheumatic care& the value of multidisciplinary medical organizations.
New Study: Upadacitinib Is Treatment Option for Giant Cell Arteritis
Results of the international SELECT-GCA study suggest that upadacitinib may be an effective new oral treatment for giant cell arteritis.
Doctoring Differently, Part 2
In part 2 of Dr. Sam Shapiro’s journey, learn how she connected with the rheumatology community to change her career and found a better way to embrace her passions for clinical rheumatology, education and helping patients.
FDA Approves Upadacitinib for GCA
Supported by data in patients with new-onset and relapsing giant cell arteritis (GCA), the FDA approved upadacitinib for the treatment of adults with GCA.
Incarcerated Individuals with Rheumatic Conditions
In addition to the impediments to consistent, high-quality care suffered by all incarcerated individuals, incarcerated patients with rheumatic disease face challenges specific to the treatment, management & monitoring of rheumatic conditions.
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 63
- Next Page »